Universal reference book for medicines
Product name: CERETON ® (CERETON)

Active substance: choline alfoscerate

Type: Nootropic drug.
Holinomimetics of central action
Producer: FarmThirm SOTEKS (Russia) manufactured by EUROPA-BIOFARM (Russia)

Composition, form of production and packaging
gelatinous soft, oval in shape, yellow or yellow with a light brown hue;
the contents of the capsules are an oily transparent colorless or slightly colored liquid.
1 caps.

choline alfoscerate 400 mg

Excipients: glycerol - 50 mg, purified water - until a weight of 590 mg is obtained.

Capsule composition: gelatin, sorbitol, glycerol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, titanium dioxide, iron oxide, yellow oxide, purified water.

14 pcs.
- packings of cellular contour (1) - packs cardboard.
14 pcs.
- packings cellular planimetric (2) - packs cardboard.
14 pcs.
- packings cellular planimetric (3) - packs cardboard.
14 pcs.
- packings cellular planimetric (4) - packs cardboard.
The solution for intravenous and intravenous administration is clear, colorless.

1 ml of 1 amp.

choline alphoscerate polyhydrate (in terms of anhydrous choline alphoscerate) 250 mg 1 g

Auxiliary substances: water d / u - up to 4 ml.

4 ml - ampoules of colorless glass (3) - packings of cellular contour (1) - packs cardboard.

4 ml - ampoules of colorless glass (3) - packings of cellular contour (2) - packs cardboard.

4 ml - ampoules of colorless glass (5) - packings of cellular contour (1) - packs cardboard.

4 ml - ampoules of colorless glass (5) - packings of cellular contour (2) - packs cardboard.


Description of the drug approved by the manufacturer for the printed edition of 2017.


Nootropic preparation.
Cholinomimetics of central action, which contains 40.5% of metabolically protected choline.
Metabolic protection contributes to the release of choline in the brain.
Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation. Increases the linear velocity of blood flow on the side of traumatic brain injury, promotes normalization of spatiotemporal characteristics of spontaneous bioelectric activity of the brain, regression of focal neurological symptoms and restoration of consciousness. Has a positive effect on cognitive and behavioral reactions of patients with cerebral vascular diseases (discirculatory encephalopathy and residual phenomena of cerebral circulation disorders).
Provides a preventive and corrective effect on pathogenetic factors of the involutionary psychoorganic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity.
Stimulates a dose-dependent release of acetylcholine under physiological conditions. Participating in the synthesis of phosphatidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, receptor function.
Has no effect on the reproductive cycle and does not have a teratogenic, mutagenic effect.


Suction and distribution

With parenteral application, absorption is 88%, it easily penetrates the BBB (with oral intake, the concentration in the brain is 45% of that in the plasma).
It accumulates mainly in the brain, lungs and liver.

85% of the drug is excreted in the form of carbon dioxide, the rest (15%) is excreted by the kidneys and through the intestine.


- acute and recovery periods of severe craniocerebral trauma and ischemic stroke, the recovery period of hemorrhagic stroke, with focal hemispheric symptoms or symptoms of brain stem damage;

- psycho-organic syndrome in the background of degenerative and involuntary changes in the brain;

- Cognitive impairment (impaired mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate), incl.
with dementia and encephalopathy;
- senile pseudo-melancholy.


In acute conditions , I / in (slowly) or deep in / m (slowly) at 1000 mg (1 ampoule) per day for 10-15 days.

In the recovery period of craniocerebral trauma, ischemic or hemorrhagic stroke, Cereton ® is prescribed 800 mg in the morning and 400 mg in the afternoon for 6 months.

In chronic cerebrovascular insufficiency and dementia syndromes, Cereton ® is prescribed 400 mg 3 times / day, preferably after meals, for 3-6 months.


Possible: nausea (mainly due to dopaminergic activation).
No withdrawal of the drug is required, in this case the dose is temporarily reduced.
Other: allergic reactions.


- hypersensitivity to the drug;

- acute stage of hemorrhagic stroke (for oral administration);

- Pregnancy;

- the period of breastfeeding;

- Children under 18 years of age (for oral administration) (due to the lack of sufficient data to date);


The drug is contraindicated in pregnancy and lactation (breastfeeding).


Contraindicated in children and adolescents under 18 years.


The application is possible according to the dosing regimen


Impact on the ability to drive vehicles and manage mechanisms

Tsereton ® does not affect the speed of psychomotor reactions.


Symptoms: nausea.

Treatment: conduct symptomatic therapy.


Clinically significant drug interaction of the drug Tsereton ® with other drugs has not been revealed.


The drug is released by prescription.


The drug should be stored out of reach of children, protected from light at a temperature of no higher than 25 ° C.
The shelf life of the capsules is 3 years, the solution for intravenous and / or injection is 5 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!